Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies
Frontiers in Immunology · 13.05.2024 · 15
DOI: 10.3389/fimmu.2024.1385484 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 13.05.2024. Verfasst von Siena M Mantooth und 4 weiteren Autor:innen. Beteiligte Einrichtung: Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina at Chapel Hill, Raleigh, NC, United Stat…. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunotherapy. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Breast cancer poses one of the largest threats to women’s health. Treatment continues to improve for all the subtypes of breast cancer, but some subtypes, such as triple negative breast cancer, still present a significant treatment challenge. Additionally, metastasis and local recurrence are two prevalent problems in breast cancer treatment. A newer type of therapy, immunotherapy, may offer alternatives to traditional treatments for difficult-to-treat subtypes. Immunotherapy engages the host’s immune system to eradicate disease, with the potential to induce long-lasting, durable responses. However, systemic immunotherapy is only approved in a limited number of indications, and it benefits only a minority of patients. Furthermore, immune related toxicities following systemic administration of potent immunomodulators limit dosing and, consequently, efficacy. To address these safety considerations and improve treatment efficacy, interest in local delivery at the site of the tumor has increased. Numerous intratumorally delivered immunotherapeutics have been and are being explored clinically and preclinically, including monoclonal antibodies, cellular therapies, viruses, nucleic acids, cytokines, innate immune agonists, and bacteria. This review summarizes the current and past intratumoral immunotherapy clinical landscape in breast cancer as well as current progress that has been made in preclinical studies, with a focus on delivery parameters and considerations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina at Chapel Hill, Raleigh, NC, United States.
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
- Cancer Research Institute, New York, NY, United States.
Zitieren
APA
Mantooth, S. M., Abdou, Y., Saez-Ibañez, A. R., Upadhaya, S., & Zaharoff, D. A. (2024). Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1385484
Vancouver
Mantooth SM, Abdou Y, Saez-Ibañez AR, Upadhaya S, Zaharoff DA. Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies. Frontiers in Immunology. 2024;15. doi:10.3389/fimmu.2024.1385484
BibTeX
@article{Mantooth2024,
author = {Mantooth, Siena M and Abdou, Yara and Saez-Ibañez, Ana Rosa and Upadhaya, Samik and Zaharoff, David A},
title = {Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies},
journal = {Frontiers in Immunology},
year = {2024},
volume = {15},
doi = {10.3389/fimmu.2024.1385484}
}
EUVIMED